Related Experiment Video
Updated: Jul 25, 2026

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
Published on: February 1, 2017
[Chronic hepatitis-b-virus infections: new options for antiviral therapy]
R A de Man1, P Honkoop, H L Janssen
1Academisch Ziekenhuis Rotterdam-Dijkzigt, afd. Maag-, Darm- en Leverziekten. devlaming@inw2.azr.nl
Abstract:
The possibilities for antiviral treatment of patients with chronic hepatitis B virus (HBV) infections have been in flux for the last few years. Apart from interferon alpha, oral nucleoside analogues are given a place. The treatment focuses on the group of patients with active virus multiplication (hepatitis B e antigen (HBeAg) and HBV DNA are demonstrable), abnormal liver enzyme values and histologically demonstrated inflammatory activity in the liver. For the individual patient the pros and cons of protracted virus inhibition should be weighted by means of an orally administered nucleoside analogue such as lamivudine, immunostimulation with injections of interferon alpha or a combination of these two.
More Related Videos
Related Concept Videos
Retrovirus Life Cycles
Viruses with RNA Genomes
Hepatitis
Inhibitors of Viral Protein Synthesis
Antiviral Nucleoside Inhibitors
Viral Hepatitis I: Introduction

